Alumis (ALMS) Change in Account Payables (2023 - 2025)
Alumis (ALMS) posted quarterly Change in Account Payables of $5.6 million for Q4 2025, up 74.31% year-over-year from $3.2 million in Q4 2024, and up 153.24% quarter-over-quarter from -$10.4 million in Q3 2025.
Analysis
Alumis (ALMS) Change in Account Payables (2023 - 2025) Analysis & Trends
Alumis (ALMS) has reported Change in Account Payables for 3 consecutive years, with $5.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Account Payables rose 74.31% year-over-year to $5.6 million; the TTM figure through Dec 2025 stood at -$6.0 million (down 170.96% YoY), while the FY2025 annual figure was -$6.0 million, down 170.96% from the prior year.
- Change in Account Payables advanced to $5.6 million in Q4 2025 per ALMS's latest filing, from -$10.4 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $5.7 million in Q1 2024 and bottomed at -$10.4 million in Q3 2025.
- Historically, Change in Account Payables has averaged $116200.0 across 3 years, with a median of $1.5 million in 2023.
- Annual changes were most pronounced in 2024 — Change in Account Payables soared 196.87% — and 2025, when it slumped 322.71%.
- Alumis' Change in Account Payables stood at -$3.3 million in 2023, then jumped by 196.87% to $3.2 million in 2024, then soared by 74.31% to $5.6 million in 2025.
- Business Quant data shows ALMS's Change in Account Payables at $5.6 million in Q4 2025, -$10.4 million in Q3 2025, and $989000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | Alumis | 1.43 Bn | 924.11 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 5.55 Mn |
| Sep 30, 2025 | -10.42 Mn |
| Jun 30, 2025 | 989,000.00 |
| Mar 31, 2025 | -2.15 Mn |
| Dec 31, 2024 | 3.18 Mn |
| Sep 30, 2024 | -2.47 Mn |
| Jun 30, 2024 | 2.07 Mn |
| Mar 31, 2024 | 5.72 Mn |
| Dec 31, 2023 | -3.29 Mn |
| Sep 30, 2023 | 1.98 Mn |